StockData
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. (VTVT) stock

VTVTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3062% below fair value
$16.23−1.06 (-6.13%)

Close on Nov 18, 2026Market cap $64.17MP/E –Yield –

vTv Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

vTv Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$16.76M. For fiscal 2025 it was -$25.26M. The highest annual figure on record is -$16.02M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.26M–
FY2024Dec 31, 2024-$25.31M–
FY2023Dec 31, 2023-$19.08M–
FY2022Dec 31, 2022-$16.02M–
FY2021Dec 31, 2021-$19.31M–
FY2020Dec 31, 2020-$18.00M–
FY2019Dec 31, 2019-$23.02M–
FY2018Dec 31, 2018-$26.86M–
FY2017Dec 31, 2017-$44.56M–
FY2016Dec 31, 2016-$48.21M–
FY2015Dec 31, 2015-$36.95M–
FY2014Dec 31, 2014-$30.78M–
FY2013Dec 31, 2013-$41.68M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.44M–
Q1 FY2026Mar 31, 2026$9.15M–
Q4 FY2025Dec 31, 2025-$9.25M–
Q3 FY2025Sep 30, 2025-$5.22M–
Q2 FY2025Jun 30, 2025-$5.10M–
Q1 FY2025Mar 31, 2025-$5.69M–
Q4 FY2024Dec 31, 2024-$4.83M–
Q3 FY2024Sep 30, 2024-$6.42M–
Q2 FY2024Jun 30, 2024-$6.73M–
Q1 FY2024Mar 31, 2024-$7.34M–
Q4 FY2023Dec 31, 2023-$2.91M–
Q3 FY2023Sep 30, 2023-$4.83M–
Q2 FY2023Jun 30, 2023-$6.17M-973.5%
Q1 FY2023Mar 31, 2023-$5.17M–
Q4 FY2022Dec 31, 2022-$6.88M–
Q3 FY2022Sep 30, 2022-$8.83M–
Q2 FY2022Jun 30, 2022$706.00K–
Q1 FY2022Mar 31, 2022-$1.02M–
Q4 FY2021Dec 31, 2021-$6.42M–
Q3 FY2021Sep 30, 2021-$3.59M–
Q2 FY2021Jun 30, 2021-$4.00M–
Q1 FY2021Mar 31, 2021-$5.30M–
Q4 FY2020Dec 31, 2020-$2.21M–
Q3 FY2020Sep 30, 2020-$5.43M–
Q2 FY2020Jun 30, 2020-$4.79M–
Q1 FY2020Mar 31, 2020-$5.56M–
Q4 FY2019Dec 31, 2019-$5.88M–
Q3 FY2019Sep 30, 2019-$6.20M–
Q2 FY2019Jun 30, 2019-$5.50M–
Q1 FY2019Mar 31, 2019-$5.45M–
Q4 FY2018Dec 31, 2018-$5.87M–
Q3 FY2018Sep 30, 2018-$6.26M–
Q2 FY2018Jun 30, 2018-$9.33M–
Q1 FY2018Mar 31, 2018-$5.40M–
Q4 FY2017Dec 31, 2017-$6.33M–
Q3 FY2017Sep 30, 2017-$11.78M–
Q2 FY2017Jun 30, 2017-$12.64M–
Q1 FY2017Mar 31, 2017-$13.82M–
Q4 FY2016Dec 31, 2016-$11.43M–
Q3 FY2016Sep 30, 2016-$12.73M–

More vTv Therapeutics figures

See a number that looks wrong?